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We investigated whether soluble EBV gH/gL (sgH/gL) functions in fusion and made a series of
truncations of gH/gL domains based on the gH/gL crystal structure. We found sgH/gL failed to mediate
cell–cell fusion both when co-expressed with the other entry glycoproteins and when added
exogenously to fusion assays. Interestingly, sgH/gL inhibited cell–cell fusion in a dose dependent
manner when co-expressed. sgH/gL from HSV was unable to inhibit EBV fusion, suggesting the inhibition
was speciﬁc to EBV gH/gL. sgH/gL stably binds gp42, but not gB nor gH/gL. The domain mutants, DI/gL,
DI-II/gL and DI-II-III/gL were unable to bind gp42. Instead, DI-II/gL, DI-II-III/gL and sgH/gL but not DI/gL
decreased the expression of gp42, resulting in decreased overall fusion. Overall, our results suggest that
domain IV may be required for proper folding and the transmembrane domain and cytoplasmic tail of
EBV gH/gL are required for the most efﬁcient fusion.
& 2012 Elsevier Inc. All rights reserved.Introduction
Epstein-Barr virus (EBV), a member of the herpesvirus family, is
transmitted orally and infects the majority of the adult population.
Infant and young childhood infections are asymptomatic or
subclinical whereas adulthood infections typically result in infectious
mononucleosis (Rickinson and Kieff, 2007). Signiﬁcantly, EBV is
associated with lymphoid malignancies as well as epithelial malig-
nancies, for which immunodeﬁcient patients are at particular risk
(Bieging et al., 2010; Longnecker, 1998; Rickinson and Kieff, 2007;
Takada, 2001; Thompson and Kurzrock, 2004; Wei and Sham, 2005).
Members of the herpesvirus family are large enveloped DNA
viruses, which use a conserved set of glycoproteins for the
complex process of viral fusion with the host cell membrane
either at the plasma membrane or following endocytosis
(Connolly et al., 2011). The majority of herpesviruses use two or
more receptors to dictate cell tropism and spread. EBV uses
different glycoprotein and receptor combinations to infect oral
epithelial cells than it does to infect B cells where it establishes
latency until reactivation. In B cells, HLA class II receptor bindingll rights reserved.
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R. Longnecker).by gH/gL/gp42 complexes triggers conformational changes that
result in activation of gB-dependent fusion between the viral
envelope and a cellular membrane (Haan et al., 2000; Li et al.,
1997; McShane et al., 2003; Spriggs et al., 1996). In epithelial
cells, which typically lack HLA class II, binding to an epithelial
receptor, such as integrins by gH/gL, presumably triggers
conformational changes that result in activation of gB and fusion
(Chen et al., 2012; Chesnokova and Hutt-Fletcher, 2011; Chesnokova
et al., 2009). EBV virions exiting B cells primarily contain the bipartite
complex gH/gL and infect epithelial cells efﬁciently, whereas virions
exiting epithelial cells primarily contain the tripartite complex gH/gL/
gp42 and infect B cells efﬁciently (Borza and Hutt-Fletcher, 2002).
When added exogenously, sgp42 enhanced B cell fusion but inhibited
epithelial fusion (Kirschner et al., 2006). The cytoplasmic domains for
both gp42 and the HSV functional homolog, gD, are not required for
cell–cell fusion, since the soluble forms of both gp42 and gD are
functional in fusion (Atanasiu et al., 2010; Sorem et al., 2009).
The recently solved x-ray crystallographic structures of gH/gL
from EBV, and HSV-2 as well as the partial gH structure of
psuedorabies virus (PRV) suggest striking conservation of gH/gL
within the herpesvirus family (Backovic et al., 2010; Chowdary
et al., 2010; Matsuura et al., 2010). The EBV structure suggests
four sequential semiautonomous domains: Domain I, II, III and IV
(DI, DII, DIII and DIV) (Matsuura et al., 2010). EBV gL forms a
stable heterodimer with the N-terminal residues of gH to form DI.
gL is an integral part of the DI structure and is required for the
export of gH to the cellular membrane (Pulford et al., 1995;
Yaswen et al., 1993). DI is composed of mixed parallel/antiparallel
Fig. 1. Schematic representation of wild type gH, FLAG tagged sgH, DI-II-III, DI-II
and DI gH mutants, and gL. (A) Approximate location of gH functional domains are
shown including the signal sequence (residues 1–17), DI (residues 18–65),
DII (residues 66–344), DIII (residues 345–529), DIV (residues 530–679), trans-
membrane domain (residues 680–698) and the cytoplasmic tail (residues
699–706). (B) FLAG tagged mutants: sgH, DI-II-III, DI-II, DI are all C-terminally
tagged with the FLAG epitope followed by a stop codon, as indicated. None of the
mutants contain the transmembrane domain nor the cytoplasmic tail of gH.
(C) Wild type gL includes the signal sequence (residues 1–23) followed by a single
domain (residues 24–137).
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supported by a layer of three helices. The three helix layer of DI
forms a wall of charged and polar residues which may interact
with other viral proteins involved in the core fusion machinery.
Between DI and DII there is a single a-helix linker which has been
proposed to act as a ‘‘hinge’’. DII is composed of an eight stranded
anti-parallel b sheet (‘‘picket fence’’) followed by an anti-parallel
ﬁve helix bundle. Projecting from the picket fence is a prominent
KGD loop that is implicated in binding gp42, as well as a gH/gL
epithelial receptor, presumably integrin avb6, avb8 or avb5
(Chen et al., 2012; Chesnokova et al., 2009). DIII consists of a
total of nine helices, the ﬁrst ﬁve of which spiral down DII and
the last four form a distinct subdomain bundle. DIV consists of
two connected anti-parallel b sheets forming a ‘‘b-sandwich’’.
Elucidation of the gH/gL structure provides a basis for deletion
and mutagenesis studies aimed at understanding the function of
gH in the core fusion machinery.
The N-terminal residues as well as the C-terminal residues of
EBV gH/gL have been implicated in promoting membrane fusion.
When EBV gL residues 54 and 94 were replaced with those of
rhesus lymphocryptovirus (Rh-LCV) gL, the mutant gL showed
wild-type expression but decreased fusion activity. Fusion could
be restored by replacing EBV gB with Rh gB, suggesting gL
interacts with gB in a species-speciﬁc manner to activate mem-
brane fusion (Plate et al., 2009). Interestingly, a single substitu-
tion in the C-terminal Domain IV, G594A, resulted in complete
abrogation of fusion with both B cells and epithelial cells, whereas
the substitution E595A reduced fusion with epithelial cells but
greatly enhanced fusion with B cells (Wu and Hutt-Fletcher,
2007).
Mutational studies of herpes simplex virus type 1 (HSV-1) gH
have been more extensive and suggest that the transmembrane
domain as well as the cytoplasmic tail of gH/gL plays an
important role in membrane fusion. Harman et al. found that
gH lacking the authentic transmembrane or cytoplasmic tail
was unable to mediate cell–cell fusion (Harman et al., 2002).
In addition, a conserved glycine residue at position 812 within
the transmembrane domain was found to be crucial for fusion
(Harman et al., 2002). Interestingly, fusion is unaffected by
deletion of the ﬁnal six residues of the gH cytoplasmic tail
(residues 832 to 838), however further deletions decreased
polykaryocyte formation by a syncytial HSV strain (Browne
et al., 1996; Wilson et al., 1994). Maintenance of the valine at
position 831 within the serine–valine–proline motif of the cyto-
plasmic tail was of particular importance for fusion (Wilson et al.,
1994). The addition of a linker insertion at residue 824, which
borders the junction between the transmembrane and the cyto-
plasmic tail, completely abrogated fusion (Jackson et al., 2010).
gD-glycophosphatidylinositol (gDgpi), in which the transmem-
brane and cytoplasmic tail of gD is replaced with a gpi linkage,
promoted fusion to near wild-type levels (Jones and Geraghty,
2004). However, gHgpi and gBgpi were unable to promote fusion,
suggesting glycoprotein speciﬁc transmembrane and cytoplasmic
tails are required for gH and gB. In contrast, more recent work has
shown that puriﬁed HSV-2 sgH/gL protein, lacking the transmem-
brane and cytoplasmic tail, can induce a modest (2.1% of wild
type) level of fusion of nectin-1-bearing C10 cells expressing gB
and gD (Atanasiu et al., 2010). Interestingly, EBV sgH/gL puriﬁed
from insect cells does not promote fusion when added exogen-
ously (Kirschner et al., 2006).
To rigorously rule out that the source of the sgH/gL is not
playing any role in the observed functional differences between
the HSV and EBV studies, we expressed and tested sgH/gL in
mammalian cells a in cell–cell fusion assay. We generated a
soluble form of gH/gL and either co-expressed it with the other
entry glycoproteins or added it exogenously to the core fusionmachinery. Our results indicate that sgH/gL does not function
efﬁciently in fusion and instead inhibits fusion. We generated domain
deletion mutants of gH to try to map the region responsible for
inhibition of fusion. We found only full length sgH/gL was able to
bind gp42, suggesting DIV of gH is required for gp42 binding.
Surprisingly, however, we found DI-II/gL, DI-II-III/gL and the full
length sgH/gL all reduce gp42 expression levels. Overall, our results
support previous observations that anchoring of gH in the membrane
is essential for most efﬁcient fusion.Results
Construction of gH/gL FLAG-tagged mutants
Recent x-ray crystallography results suggest that gH/gL is
composed of four semi-autonomous domains: DI, DII, DIII and
DIV. To study whether sgH/gL could mediate fusion, we con-
structed soluble C-terminal deletion variants of gH, incorporating
the FLAG epitope at the C-terminus of each (Fig. 1). Mutant sgH
(consisting of the full ectodomain: DI-II-III-IV) was truncated at
amino acid 679, immediately upstream of the transmembrane
domain and cytoplasmic tail which was replaced with the FLAG
tag followed by a stop codon. Mutants DI-II-III, DI-II and DI were
truncated at residues 529, 344 and 65 respectively, and
C-terminally tagged with the FLAG epitope followed by a stop
codon. We chose to add the FLAG epitope at the C-terminus of the
truncations to allow us to readily monitor expression of the
proteins and verify they were full length.
Expression and secretion of soluble gH/gL domain mutants
To determine whether the FLAG-tagged gH mutants were
expressed and produced as soluble forms, plasmids encoding
each of the mutants together with gL were transfected into
CHO-K1 cells and protein expression was analyzed 48 h post-
transfection by Western Blot. We found that all of the mutants
were expressed in cellular extracts at the approximate expected
molecular weight (DI, 7 kDa; DI-II, 38 kDa; DI-II-III, 58 kDa; sgH
74 kDa), as determined by probing with an anti-FLAG antibody
(Fig. 2A). However, only DI and sgH were detected as distinct
bands in cell culture supernatants (Fig. 2B). DI, DI-II, DI-II-III, as
well as sgH all tended to form higher molecular weight aggre-
gates in cell lysates (intracellularly) and in culture supernatants
(extracellularly), although DI to a lesser extent. The aggregates
(indicated by an arrow, Fig. 2B) could not be resolved by changing
Fig. 2. sgH/gL mutants are expressed. CHO-K1 cells were transiently transfected
with (A) empty vector (pCAGGS), wild type gp42 with DI/gL, wild type gp42 with
DI-II/gL, wild type gp42 with DI-II-III/gL and wild type gp42 with sgH/gL. Forty
eight hours post transfection cells were lysed in Triton X-100 lysis buffer
containing protease inhibitors and analyzed by 12% SDS-PAGE and Western
blotting with polyclonal anti-FLAG antibody (F7425-Sigma). (B) Empty vector
(pCAGGS), DI/gL, DI-II/gL, DI-II-III/gL and sgH/gL. Forty eight hours post transfec-
tion supernatant was collected and analyzed by 4–20% SDS-PAGE and Western
blotting with polyclonal anti-FLAG antibody (F7425-Sigma). Size markers in kilo
Dalton are noted to the right and left of the blots. Aggregates are indicated by
an arrow.
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Fig. 3. sgH/gL binds gp42 but not gB nor gH when co-expressed. (A) CHO-K1 cells
were co-transfected with sgH/gL and either vector alone, gB, gp42, or gH/gL.
Binding of sgH/gL was measured by cELISA using anti-FLAG-M2 (F1804; Sigma),
secondary biotinylated anti-mouse IgG antibody, tertiary streptavidin-HRP and
TMB substrate. Color development was measured by absorbance at 370 nm.
Binding was normalized to gp42 binding levels, which were set to 100%. Data
shown are representative results of three independent experiments. (B) CHO-K1
cells were co-transfected with DI-gL, DI-II/gL, DI-II-III/gL and sgH/gL. Forty eight
hours post transfection, protein supernatants were collected and overlaid on CHO-
K1 cells transiently transfected with either vector alone (gray bars) or gp42 (dark
gray bars) for 48 h. Binding was normalized to gp42 binding levels, which were set
to 100%. Data shown are representative results of three independent experiments.
Error bars represent standard deviations for the normalized values.
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sion system prior to loading on SDS-PAGE gels (data not shown).
sgH/gL is secreted, binds gp42, and is therefore properly folded
To study whether the expressed sgH/gL domain mutants were
functional, we analyzed their ability to bind other EBV glyco-
proteins involved in viral entry and fusion by cELISA (Cell-based
Enzyme-Linked Immunosorbent Assay). We co-transfected
CHO-K1 cells with plasmids encoding sgH/gL and either vector,
gB, gp42 or wild type gH/gL and detected sgH/gL binding using an
anti-FLAG antibody. We found sgH/gL was efﬁciently tethered to
the cell surface by virtue of binding gp42, but not gB, nor
wild type gH/gL, as expected (Fig. 3A). We next tested the
ability of exogenously-expressed sgH/gL domain mutants to bind
gp42 using a monolayer binding assay. CHO-K1 cells were
co-transfected with plasmids encoding DI/gL, DI-II/gL, DI-II-III/gL
or sgH/gL. Supernatants, harvested after two days, were overlaid
for 1 h at 4 1C onto CHO-K1 monolayers transfected with wild
type gp42. Following extensive washing, binding to gp42 wasdetected by cELISA using an anti-FLAG antibody. We found that
none of the sgH/gL protein supernatants bound CHO-K1 cells
transfected with vector alone. Only sgH/gL containing all four gH/
gL domains and none of the domain deletion mutants was able to
bind gp42 (Fig. 3B). It is possible that the DI/gL mutant was
unable to bind gp42 because gp42 binds at the groove formed by
both DI/gL and DII. This would suggest that DI/gL and DII are
functionally non-autonomous. Unexpectedly, however, the DI-II/
gL and DI-II-III/gL mutants also failed to bind gp42 suggesting
that misfolding or aggregation of the protein may in part be the
cause of loss of gp42 binding for these mutants. Alternatively, our
data suggests that all four domains may be required for proper
folding or solubility of gH/gL in order to bind gp42.
To ensure that the lack of binding of DI/gL, DI-II/gL, and DI-II-
III/gL was not due to insufﬁcient quantities of soluble protein, we
quantitated the protein bands on the Western Blot (Fig. 2B) and
normalized them against sgH/gL using Licor software. We then
repeated the binding assay using equal or three times excess
amounts of the DI/g, DI-II/gL, DI-II-III/gL compared with sgH/gL.
We found that DI/g, DI-II/gL, and DI-II-III/gL were unable to bind
gp42 even in these excess amounts (data not shown). We
conﬁrmed our results using independent supernatants collected
on a different day and quantitated protein bands on Western Blot
by licor and found similar results.sgH/gL does not efﬁciently mediate fusion
To assess the ability of sgH/gL to mediate fusion, we performed
a cell–cell fusion assay in which CHO-K1 effector cells
co-transfected with plasmids encoding the EBV glycoproteins
%
Fu
si
on
HLA HLA
V gp42, gH/gL, gB gp42, gH/gL, gB gp42,sgH/gL, gB
100
120
60
80
0
20
40
Target
Effector
1 2   3 4
Fig. 4. sgH/gL does not function in fusion when co-transfected or when added exogenously. CHO-K1 target cells were transiently co-transfected with HLA-DR and T7
polymerase. CHO-K1 effector cells were transiently co-transfected with gp42, gB and either wild type gH/gL (lane 2, 3) or sgH/gL (lane 4). Cells were detached 24 h post-
transfection and target cells were overlaid onto effector cells. Fusion activity was assessed 18–24 h post overlay by the addition of passive lysis buffer followed by the
addition of luciferase substrate. Luciferase activity was measured with a Perkin–Elmer Victor plate reader. Data shown are representative results of three independent
experiments. Error bars represent standard deviations for the normalized values.
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CHO-K1 target cells co-transfected with the gp42 receptor HLA
class II and T7 polymerase. Eighteen to twenty-four hours after
overlay, fusion activity was determined by quantiﬁcation of luci-
ferase activity. We found that without HLA class II, no fusion
occurs, as expected (Fig. 4, lane 1, 2). When HLA class II is present
in target cells and the effector cells express wild type gH/gL, gB,
and gp42; the cells fuse efﬁciently. This wild type condition was set
to 100% (Fig. 4, lane 3). However, when sgH/gL is co-transfected in
place of wild type gH/gL, fusion is undetectable (Fig. 4, lane 4),
suggesting that although sgH/gL is capable of binding gp42, it is not
functional for fusion. In addition, in the absence of wild type gH/gL,
exogenously added sgH/gL protein is not able to mediate fusion
(data not shown).
SgH/gL inhibits fusion in a dose dependent manner
We next investigated whether soluble gH/gL could inhibit
fusion induced by wild type gH in a dose dependent manner.
For this cell–cell fusion experiment all target cells were co-
transfected with HLA-DR and T7 polymerase (lanes 1–8). Effector
cells were transfected with vector alone (lane 1), co-transfected
with wild type gH (0.5 mg), excess gL (2.5 mg), gB (0.5 mg) and
gp42 (2 mg) (lane 2–8), or co-transfected with increasing amounts
of wild type gH or sgH (lanes 3–5 and lanes 6–8, respectively).
All of the target cells were co-transfected with HLA-DR and T7
polymerase. We found that increasing the amount of wild type
gH/gL decreased the amount of fusion initially but then fusion
remained relatively constant (around 50% of maximal levels)
(Fig. 5, compare lane 2 with lanes 3–5). In contrast, when levels
of sgH/gL were increased, fusion levels decreased in a dose
dependent manner (Fig. 5, compare lane 3–5 with lanes 6–8).
gH/gL expression decreased with increased amounts of sgH/gL,
however, whereas the gH/gL expression decreased to 70–80% of
wild type, fusion decreased to 40–80% of wild type (Fig. 5, lanes
6–8) providing data that EBV sgH/gL inhibits fusion. We found the
amount of gH expression does not increase with increasing
amounts of wild type gH/gL. It is possible that the cELISA results
are not on a linear scale or alternatively the gH/gL expression is
dependent on overall glycoprotein stoichiometry.
DI/gL is insufﬁcient for inhibition of fusion
Our previous data demonstrated that only full-length sgH/gL
bound gp42. We sought to determine if binding gp42 was themechanism by which sgH/gL inhibits fusion. We hypothesized
that if this was true, only sgH/gL would be capable of inhibiting
fusion and the truncation mutants (DI/gL, DI-II/gL and DI-II-III/gL)
would not be capable of inhibiting fusion. As a negative control,
we also assessed the ability of a soluble form of HSV-1 gH/gL to
inhibit EBV fusion. As predicted, DI/gL failed to inhibit fusion
(Fig. 6, lane 4). However, to our surprise, DI-II/gL, DI-II-III/gL and
EBV sgH/gL all inhibited fusion to a signiﬁcant degree (Fig. 6, lanes
5–7). HSV sgH/gL failed to inhibit fusion suggesting the inhibition
with DI-II/gL DI-II-III/gL and EBV sgH/gL was species speciﬁc
(Fig. 6, lane 8). This suggests that sgH/gL binding to gp42 is not
the sole mechanism by which sgH/gL inhibits fusion.
gp42 glycoprotein expression is decreased in the presence of sgH/gL
To determine if gp42 glycoprotein expression was affected
by DI/gL, DI-II/gL, DI-II-III/gL or sgH/gL co-expression, we co-
transfected CHO-K1 cells with each of the gH domain mutants
and wild type gp42 and analyzed gp42 expression by Western
blot using an anti-gp42 antibody. Wild-type gp42 is cleaved and
secreted from cells when expressed alone, however when wild
type gH/gL is expressed on the cell surface, the functional, soluble
form of gp42 binds back to cells by virtue of binding gH/gL
(Fig. 7A, lane 7). When wild type gp42 was expressed alone or
with DI/gL, the majority of the gp42 was cleaved and secreted
(Fig. 7B, lanes 2 and 3). We did not see a signiﬁcant difference in
gp42 expression in cell lysates or in supernatants when we
compared gp42 alone with gp42 co-transfected with DI/gL.
However, when gp42 was co-expressed with DI-II/gL, DI-II-III/gL
and sgH/gL, gp42 expression was decreased in the cell lysates as
well as in the supernatants (Fig. 7A and B, compare lane 2 with
lanes 4–6). Our results suggest that insufﬁcient soluble gp42
expression may account for the inhibition of fusion seen with
sgH/gL, as well as, DI-II/gL, DI-II-III/gL co-expression.Discussion
Recent data has shown that puriﬁed HSV-2 sgH/gL protein,
lacking the transmembrane and cytoplasmic tail, can induce a
modest (2.1% of wild type) level of fusion of nectin-1-bearing C10
cells expressing gB and gD (Atanasiu et al., 2010). Interestingly,
studies with cytomegalovirus (CMV) have found that membrane
bound forms of gH/gL can function in trans with gB when gH/gL
was expressed on ARPE cells and gB was expressed on HeLa cells,
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factor may be required (Vanarsdall et al., 2008). Importantly, CMV
deletions that produced soluble gH/gL did not function in fusion.
The authors proposed that both gB and gH/gL must be anchored in
the membrane to promote fusion (Vanarsdall et al., 2008). Our
ﬁnding that EBV sgH/gL does not enhance fusion when added
exogenously is consistent with our previously published results
(Kirschner et al., 2006). The differences in function of soluble gH/gL
from the different herpesviruses may reﬂect signiﬁcant differences
between the fusion complexes of gB/gH/gL/gp42 of EBV and gB/gD/
gH/gL of HSV that have not yet been identiﬁed or possibly the
experimental techniques used to analyze fusion function. For EBV
and CMV, the partnering of gH/gL with additional viral proteins
(EBV gp42, CMV UL128-131, or CMV gO) can alter tropism. Such
stable complexes have not been identiﬁed for HSV gH/gL. Perhapsthis difference contributes to the inability of soluble forms of EBV
and CMV gH/gL to promote fusion. Nevertheless, the fusion
mediated by soluble HSV gH/gL was much reduced compared to
wild-type levels (Atanasiu et al., 2010), and our data as well as the
accumulated evidence described in the introduction suggest the
transmembrane and cytoplasmic tail of gH/gL is critical for gB
mediated activation of fusion for EBV.
Interestingly, soluble forms of both gp42 and gD function in
fusion and both undergo conformational changes upon receptor
binding (Carﬁ et al., 2001; Di Giovine et al., 2011; Kirschner et al.,
2009; Krummenacher et al., 2005; Mullen et al., 2002). How this
change alters gH/gL binding and how this change is ultimately
translated to the fusogen, gB, is not completely understood. Studies
in HSV and CMV have suggested there is a direct interaction of the
ectodomains of gH/gL with gB using bi-molecular complementation
Fig. 7. gp42 expression is decreased when co-expressed with sgH/gL. CHO-K1 cells
were transiently transfected with empty vector, gp42 or gp42 with DI, DI-II/gL,
DI-II-III/gL, sgH/gL or wild type gH/gL respectively. Forty eight hours post transfec-
tion, supernatants (B) were collected and cells (A) were lysed in Triton X-100 lysis
buffer containing protease inhibitors and analyzed by 12% SDS-PAGE and Western
blotting with polyclonal anti-gp42 antibody serum (PB114). Size markers in kilo
Dalton are noted to the left of the blots. Gp42 expression was normalized to wt
gp42, wt gH/gL for cell lysates (panel A, lane 7) and to wt gp42 for supernatants
(panel B, lane1).
C.L. Rowe et al. / Virology 436 (2013) 118–126 123(Atanasiu et al., 2007) or co-immunoprecipitation (Vanarsdall et al.,
2008). Whether the cytoplasmic tail of gH/gL interacts with that of
gB and whether this is important for activation of fusion is not
understood. Alternatively, the gH/gL tail may be required for gH/gL
conformation and/or stability, gH/gL association with viral or
cellular proteins within the lipid bilayer or cytoplasm, or gH/gL
multimerization as has been previously proposed (Jackson et al.,
2010; Wilson et al., 1994).
We observed signiﬁcant inhibition of cell–cell fusion when
sgH/gL was co-expressed with wild type gH, gp42 and gB. The
observation that sgH/gL was able to bind gp42, caused us to
initially hypothesize that the mechanism of inhibition of fusion
was competitive inhibition with wild type gH/gL for binding to
gp42. Since the functional form of gp42 is soluble, sgH/gL bound
to sgp42 would be expected to no longer be membrane bound
and would not be able to mediate B cell fusion. In epithelial cells,
sgH/gL can bind a cellular receptor and prevent gH/gL from
binding to the receptor, since blocking of epithelial infection by
sgH/gL has been shown (Chen et al., 2012; Chesnokova and Hutt-
Fletcher, 2011; Chesnokova et al., 2009). Interestingly, HSV sgH/
gL produced from insect cells binds to cells independent of
"alpha"v"beta"3 integrin, inhibits virus infection and is able to
activate NF-kb by binding Toll-like receptor 2 (TLR2) (Leoni et al.,
2012). In addition, recent data on HCMV suggests gH/gL/gO may
mislocalize or block entry mediators in cytoplasmic membranes
of ﬁbroblasts whereas gH/gL/UL128-131 blocks epithelial cell
receptors (Ryckman et al., 2008; Vanarsdall et al., 2011). Speciﬁ-
cally, gO promoted the export of gH/gL from the endoplasmic
reticulum and the accumulation of gH/gL in the trans-Golgi
network. We found DI-II/gL and DI-II-III/gL inhibited fusion but
were not able to bind gp42 when added exogenously. However,we believe their propensity to form aggregates may be obscuring
their potential for binding exogenously and that they may still
bind gp42 intracellularly. DI/gL does not appear to form aggre-
gates in supernatants, does not bind gp42 and also does not
decrease gp42 expression. sgH/gL clearly bound gp42 when added
exogenously and inhibited fusion when expressed endogenously.
DI-II/gL, DI-II-III/gL and sgH/gL all decreased gp42 glycoprotein
expression. Thus, we propose that the mechanism of inhibition of
fusion by DI-II/gL, DI-II-III/gL and sgH/gL is via intracellular
binding to gp42 in the endoplasmic reticulum and targeting it
to degradation pathways, leading to a decrease in secreted and
cell associated gp42. Similarly, during B cell infection, EBV gp42
binds HLA class II intracellularly. Replacement of the invariant
chain with gp42 has been suggested to target the gp42-HLA class
II complex and any associated proteins to a degradative pathway
and prevent gp42 recognition by T cell receptors (Borza and Hutt-
Fletcher, 2002).
When we tried to map the speciﬁc gH/gL domain responsible
for binding gp42, we found all four domains are required for
proper folding of sgH/gL and binding to gp42. Although the x-ray
crystallographic structures of EBV gH/gL, PRV gH and HSV gH/L
suggested four semiautonomous domains (Backovic et al., 2010;
Chowdary et al., 2010; Matsuura et al., 2010) our truncation
mutants suggest that there are likely interdomain interactions
that are important for gH/gL folding, processing, and stability.
Further mutational analysis is necessary to test whether the large
groove between DI and DII adjacent to the gH/gL KGD motif,
thought to be the receptor binding domain of gH/gL, is a site for
gp42 binding. Maintenance of the overall protein conformation
may be required for proper binding of viral as well as cellular
proteins to gH/gL. It will be interesting to see if PRV and HSV gH/
gL have similar multi-domain interaction requirements.Methods
Cells and antibodies
Chinese Hamster Ovary cells (CHO-K1) were grown in 75-cm2
cell culture ﬂasks (Corning) in Ham’s F-12 medium (Bio-
Whittaker) supplemented with 10% fetal bovine serum (HyClone)
and 1% penicillin–streptomycin (BioWhittaker). Trypsin-Versene
(BioWhittaker) was used to detach adherent cells. Polyclonal
anti-gp42 antibody serum (PB114) was used as previously
described (McShane et al., 2003). Monoclonal antibody 3H3
(anti-gp42) was obtained as previously described (Kirschner
et al., 2006). Monoclonal anti-FLAG M2 antibody (F1804) and
polyclonal anti-FLAG antibody (F7425) were obtained from
Sigma-Aldrich Chemical Company.
Plasmids
FLAG tagged EBV DI, DI-II, DI-II-III and sgH were generated by
PCR ampliﬁcation from wild type gH in pCAGGS (Haan et al.,
2001) using the N-terminal primer 5’-CCGCTCGAGCGGGACCATG-
CAGTTGCTCTGTG-3’ and the following C-terminal FLAG tagged
stop containing primers: DI primer 5’-GGAAGATCTCTACTTG-
TCGTCATCGTCTTTGTAGTCCAAATCTTCGGTGACATTTGCC-3’, DI-II
primer 5’-GGAAGATCTCTACTTGTCGTCATCGTCTTTGTAGTCTTG-
CATGCCCTTGACAGTGG-3’, DI-II-III primer 5’–GGAAGATCTC-
TACTTGTCGTCATCGTCTTTGTAGTCGAGATGCCACGCATCCCTGTC-3’
and sgH primer 5’-CGAAGATCTCTACTTGTCGTCATCGTCTTTGTA-
GTCGTGTGCTCTTTCTTCATAC-3’. The PCR products were puri-
ﬁed by Qiagen PCR puriﬁcation kit, digested with Xho I and Bgl
II, puriﬁed by Qiagen gel extraction kit and ligated into the gel
puriﬁed Xho I- and Bgl II-digested pCAGGS expression vector
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competent DH5a, and selected on ampicillin plates. DNA was
isolated from overnight cultures using the Qiagen miniprep kit,
digested to conﬁrm the presence of insert and sequenced in both
directions by the Northwestern Genomic Core Facility. Large scale
DNA preparations were isolated using Qiagen Endo-Free Plasmid
maxiprep kit and used in subsequent experiments. EBV gL in
pCAGGS was previously described (Haan et al., 2001).
HSV sgH was generated by PCR ampliﬁcation from wild type
gH (Pertel et al., 2001) in pCAGGS using the N-terminal primer
5’-GGCAGATCTGCCACCATGGGGAATGGTTTATGGTTC-3’ and the
C-terminal stop containing primer 5’-GCGAGATCTTCATTAGGGC-
GCAATTGCGGCCACGGGCTGC-3’.
The PCR products were puriﬁed by Qiagen PCR puriﬁcation kit,
digested with Bgl II, puriﬁed by Qiagen gel extraction kit and
ligated into the gel puriﬁed Bgl II-digested pCAGGS expression
vector overnight at 14 1C. The ligated products were transformed
into competent DH5a, and selected on ampicillin plates. DNA was
isolated from overnight cultures using the Qiagen miniprep kit,
digested to conﬁrm the presence of insert. Clones were sequenced
to conﬁrm directionality by the Northwestern Genomic Core
Facility. HSV gL in pCAGGS was previously described (Pertel
et al., 2001).
HLA-DRa and HLA-DRb were cloned into pSG5 (Stratagene) as
previously described (Haan et al., 2000).
Transfection
CHO-K1 cells were transfected in Opti-Mem (Gibco) medium
using Lipofectamine 2000 (Invitrogen) according to the manufac-
tures directions. Brieﬂy, 24 h after cell plating in a six well dish,
various combinations of expression vectors were transfected with
lipofectamine in Opti-Mem overnight.(i) Expression (Fig. 2A): pCAGGS (vector), wt gp 42 2 mg, DI
0.5 mg, gL 0.5 mg; wt gp 42 2 mg, DI-DII.5 mg, gL 0.5 mg; wt gp
42 2 mg, DI-DII-III 0.5 mg, gL 0.5 mg; wt gp 42 2 mg, sgH .5 mg,
gL 0.5 mg; (Fig. 2B): pCAGGS (vector) 4 mg; DI 2 mg, gL 2 mg;
DI-DII 2 mg, gL 2 mg; DI-DII-III 2 mg, gL 2 mg; sgH 2 mg, gL 2 mg.(ii) Endogenous binding (Fig. 3A): pCAGGS (vector) 4 mg; sgH
0.5 mg, gL 0.5 mg; gB 0.5 mg, pCAGGS 2.5 mg; sgH 0.5 mg, gL
0.5 mg; gp 42 2 mg, pCAGGS 1 mg; sgH 0.5 mg, gL 1 mg; wt gH
0.5 mg, pCAGGS 2 mg.(iii) Exogenous binding (Fig. 3B): pCAGGS 4 mg; wt gp 42 4 mg.
(iv) Fusion (Fig. 4): Target cells: (all lanes) T7 polymerase 0.5 mg;
(lane 1 and 2) pCAGGS 4 mg; (lane 3, 4, 5) pCAGGS 2 mg;
HLA-DRa 1 mg, HLA-DRb 1 mg; Effector cells: (all lanes) T7
luciferase 0.8 mg; (lane 1) pCAGGS 3 mg; (lane 2, 3 and 5) gp
42 2 mg, gH 0.5 mg, gL 0.5 mg, gB 0.5 mg; (lane 4) gp42 2 mg,
sgH 0.5 mg, gL 0.5 mg, gB 0.5 mg.(v) Fusion and expression (Fig. 5):Target cells: (all lanes) T7
polymerase 0.5 mg; (lane 1 and 2) pCAGGS 4 mg; (lane 3, 4, 5)
pCAGGS 2 mg; HLA-DRa 1 mg, HLA-DRb 1 mg; Effector cells:
(all lanes) T7 luciferase 0.8 mg; gp42 2 mg, gL 2.5 mg, gB
0.5 mg; (lane 2) gH 0.5 mg; (lane 3) gH 1 mg; (lane 4) gH
1.5 mg; (lane 5) gH 2 mg; (lane 6) gH 0.5 mg, sgH 0.5 mg; (lane
7) gH 0.5 mg, sgH 1 mg; (lane 8) gH 0.5 mg, sgH 1.5 mg.(vi) Fusion and expression (Fig. 6): Target cells: (all lanes) T7
polymerase 0.5 mg; (lane 1 and 2) pCAGGS 4 mg; (lane 3, 4, 5)
pCAGGS 2 mg; HLA-DRa 1 mg, HLA-DRb 1 mg; Effector cells:
(all lanes): T7 luciferase 0.8 mg; gp42 2 mg, gL 2.5 mg, gB
0.5 mg; (lane 2–7) gH 0.5 mg; (lane 3) gH 1 mg; (lane 4) HSV
sgH 1 mg; HSV gL 1 mg; (lane 5) DI 1 mg; (lane 6) DI/II 1 mg;
(lane 7) DI/II/III 1 mg; (lane 8) sgH 1 mg.(vii) gp42 expression (Fig. 7): (all lanes) gp42 2 mg; (lane 1)
pCAGGS 1 mg; (lane 2) DI 0.5 mg, gL 0.5 mg; (lane 3) DI/II0.5 mg, gL 0.5 mg; (lane 4) DI/II/III 0.5 mg; gL 0.5 mg; (lane 5)
sgH 0.5 mg gL 0.5 mg (lane 6) wt gH 0.5 mg, gL 0.5 mg.Western blotting
CHO-K1 cells were transfected as described above. The
medium was changed 16 h post transfection to complete Ham’s
F12 medium and cells and culture supernatants were collected at
48 h post transfection. Cells were detached with Versene, washed
with PBS, and lysed using a 1% Triton X-100 buffer containing
protease inhibitors (1ml of lysis buffer/10 million cells). Culture
supernatants were collected prior to cell detachment and spun
down to pellet detached cells. Supernatants and lysates were run
on 4–20% Bio-Rad Criterion gels (Fig. 2B) and 12% Bio-Rad
Criterion gels (Figs. 2A and 7) in sodium dodecyl sulfate (SDS)
sample buffer at 90 V for l.5 h. Proteins were transferred to
Whatman Optitran 0.45 mm nitrocellulose membrane in transfer
buffer at 100 V for 90 min. Blots were blocked in Tris-buffered
saline with 5% milk for 1 h at room temperature or overnight at
4 1C and then incubated for 2 h at room temperature with
polyclonal anti-FLAG antibody (Sigma, F7425) 1:1000 (Fig. 2) or
polyclonal anti-gp42 antibody serum (PB114) 1:2000 (Fig. 7) in
blocking solution, as previously described (Fan and Longnecker,
2010; McShane et al., 2003). Blots were washed and IRDyes 800
CW conjugated goat (polyclonal) anti-rabbit IgG (HþL) (Li-Cor
biosciences, 926-32211) 1:10,000 in blocking solution was
applied for 1 h at room temperature with an aluminum foil cover.
The blots were washed and analyzed with Li-Cor Biosciences
Odysseys infared imaging studio software.
Cell enzyme-linked immunosorbent assay (cELISA)
cELISA was used to determine sgH binding (Fig. 3A). Brieﬂy,
CHO-K1 cells were co-transfected in a six well dish with each of
the FLAG tagged mutants and wild-type gp42, gB or wild type gH.
The medium was changed 16 h post transfection and 1 h later the
cells were detached with Versene, counted using a Beckman
Colter Z1 particle counter, 37,500 cells were transferred to a 96
well plate and the total volume was adjusted to 150 ml with
complete Ham’s F12 medium. Twenty-four hours later cells were
washed once with phosphate-buffered saline (PBS), and cELISA
was performed using the monoclonal antibody anti-FLAG-M2
(F1804; Sigma). After incubation with antibody, the cells were
washed, ﬁxed, and incubated with biotinylated goat anti-mouse
IgG (Sigma), followed by streptavidin-horseradish peroxidase
(HRP) (GE Healthcare) and TMB one component HRP substrate
(BioFX). Absorbance readings were taken at 380 nm using a
Wallac-Victor luminometer (Perkin–Elmer).
cELISA and fusion assay
CHO-K1 cells were transiently transfected as described above.
The medium was changed 16 h post transfection and the cells
were detached with Versene and 37,500 cells were transferred to
duplicate 96-well plates, one plate was used for cELISA with
monoclonal anti-gp42 antibody (3H3) and the other plate was
overlaid with equal numbers of CHO-K1 target cells transfected
with T7 polymerase and HLA-DRa 1 mg, HLA-DRb. The total
volume was adjusted to 150 ml with complete Ham’s F12
medium. Eighteen to twenty hours after overlay, cells were
washed with PBS and lysed for 10 min with 50 ml passive lysis
buffer (Promega) per well. Luciferase activity was measured with
a Perkin–Elmer Victor plate reader immediately after addition of
50 ml/well of luciferase reagent (Promega).
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A ‘‘monolayer binding assay’’ was performed as previously
described (Fan and Longnecker, 2010) to assess the abilities of the
secreted gH mutants to bind gB, gp42 or gH (Fig. 3B). CHO-K1
cells seeded in six well plates for 24 h were transfected with
wild type gp42 using 6 ml of Lipofectamine 2000. After 24 h of
incubation, the cells were transferred to 96 well dishes in
Ham’s F12 supplemented with 10% FBS. Twenty four hours later
the cells were washed twice with cold PBS and overlayed with
each of the gH FLAG mutant protein supernatants (isolated
following 48 h transfection and normalized to each other by
Western blot, data not shown) in PBS-ABC for 1 h at 4 1C. As a
negative control, each of the FLAG mutant protein supernatants
was also overlayed onto untransfected cells. The cells were then
washed with cold PBS four times and soluble gH binding was
detected by cELISA using the monoclonal antibody anti-FLAG-M2
(F1804; Sigma) for 1 h at room temperature. After incubation
with primary antibody, the cells were washed, ﬁxed, and incu-
bated with biotinylated goat anti-mouseIgG (Sigma) for 30 min at
room temperature, followed by streptavidin-horseradish perox-
idase (HRP) (GE Healthcare) for 30 min at room temperature and
TMB one component HRP substrate (BioFX). Absorbance readings
were taken at 380 nm using a Wallac-Victor luminometer (Per-
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